Monitor for future disclosures on revenue contribution from the partnership. The agreement provides revenue visibility but lacks specific financial terms, so the near-term stock impact is uncertain. Watch for any subsequent announcements on pricing, volume, or expansion into additional European markets.
Price Chart
Executive Summary
Cosmos Health announced a five-year distribution and promotion partnership with Libytec Pharmaceutical S.A. to commercialize its type-2 diabetes drug DIABIT-IS X (generic sitagliptin) in Greece. The agreement provides revenue and cash-flow visibility but no specific financial terms were disclosed, limiting the immediate quantifiable impact.
Key Facts
- Five-year agreement for DIABIT-IS X (sitagliptin) in Greece
- Cosmos Health supplies the product; Libytec handles distribution, medical information, and promotion
- DIABIT-IS X is a generic alternative to Merck's Januvia, which with Janumet generated ~$4.5B in global sales in 2022
- Expected to be accessible through Greece's national health insurance system (EOPYY)
- No financial terms (upfront payments, revenue milestones, or minimum guarantees) were disclosed
Financial Impact
Undisclosed; five-year distribution agreement for generic sitagliptin in Greece with no stated revenue or cash-flow figures
Risk Factors
- Generic competition from other sitagliptin manufacturers
- Regulatory or pricing changes in the Greek pharmaceutical market
- Execution risk in distribution and promotion through Libytec's network
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3326385 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 8-K | $0.2530 | awaiting T+20 | — | $0.2360 (−6.72%) |
Oct 16, 2026 11d ago | SC 13G/A | $0.3250 | awaiting T+20 | — | $0.2360 (−27.38%) |
Oct 9, 2026 18d ago | 8-K | $0.3496 | awaiting T+20 | — | $0.2360 (−32.49%) |
Sep 3, 2026 7w ago | Press Release | $0.2660 $0.4300 | ▼ −61.65% | ▼ −62.77% | $0.2360 (+11.28%) |
Aug 19, 2026 9w ago | Press Release | $0.1930 | awaiting T+20 | — | $0.2360 (−22.28%) |
Jul 20, 2026 14w ago | Press Release | $0.2303 $0.2050 | ▼ −10.99% | ▼ −15.11% | $0.2360 (+2.48%) |
Jul 17, 2026 14w ago | Press Release | $0.2348 $0.2179 | ▼ −7.20% | ▼ −11.64% | $0.2360 (+0.51%) |
Jul 16, 2026 14w ago | Press Release | $0.2807 $0.2065 | ▼ −26.43% | ▼ −30.05% | $0.2360 (−15.92%) |
Jul 15, 2026 14w ago | Press Release | $0.2785 $0.2071 | ▼ −25.64% | ▼ −27.98% | $0.2360 (−15.26%) |
Jul 14, 2026 15w ago | Press Release | $0.3071 $0.2198 | ▼ −28.43% | ▼ −30.92% | $0.2360 (−23.15%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers